Corvus Pharmaceuticals
CRVS
38 hedge funds and large institutions have $55.6M invested in Corvus Pharmaceuticals in 2020 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 11 increasing their positions, 9 reducing their positions, and 6 closing their positions.
28% more capital invested
Capital invested by funds: $43.6M → $55.6M (+$12M)
22% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 9
2.72% more ownership
Funds ownership: 70.42% → 73.14% (+2.7%)
12% less funds holding
Funds holding: 43 → 38 (-5)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
67% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
+$537K |
| 2 |
Millennium Management
New York
|
+$476K |
| 3 |
Renaissance Technologies
New York
|
+$299K |
| 4 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$34.4K |
| 5 |
Russell Investments Group
London,
United Kingdom
|
+$26.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$1.23M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$248K |
| 3 |
Two Sigma Investments
New York
|
-$143K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$87.9K |
| 5 |
Morgan Stanley
New York
|
-$52.8K |
CRVS Hedge Fund Activity: Q2 2020 in Review
38 of the 4,888 institutional investors tracked by Wall St. Rank reported a position in Corvus Pharmaceuticals (CRVS) for Q2 2020, worth a combined $55.6M — up 28% from $43.6M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of CRVS and 2 opened new positions — a net loss of 4 holders — while 9 trimmed existing stakes and 11 added.
The largest buyer was Acadian Asset Management, opening a new position worth an estimated $537K. The largest seller was BVF Inc, cutting an estimated $1.23M.
- 38 institutional investors held Corvus Pharmaceuticals (CRVS) as of Q2 2020, down from 43 in Q1 2020.
- Funds reported $55.6M of Corvus Pharmaceuticals stock for Q2 2020, up 28% quarter-over-quarter.
- 2 funds opened new Corvus Pharmaceuticals positions in Q2 2020 and 6 closed out, a net change of -4 holders.
- The largest Corvus Pharmaceuticals buyer in Q2 2020 was Acadian Asset Management, an estimated $537K added.
- The largest Corvus Pharmaceuticals seller in Q2 2020 was BVF Inc, an estimated $1.23M sold.
Based on aggregated 13F filings for Q2 2020.